On December 20, 2024, the Securities and Exchange Commission (SEC or the “Commission”) announced charges against several entities that failed to ...
CP-506 is under clinical development by Convert Pharmaceuticals and currently in Phase II for Pancreatic Cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback